Objective : We aimed to evaluate the cost-effectiveness of two first-line treatments newly approved 11 in the Chinese market for the treatment of extensive-stage small-cell lung cancer (ES-SCLC), 12 namely,… Click to show full abstract
Objective : We aimed to evaluate the cost-effectiveness of two first-line treatments newly approved 11 in the Chinese market for the treatment of extensive-stage small-cell lung cancer (ES-SCLC), 12 namely, adebrelimab plus chemotherapy (carboplatin+etoposide) and serplulimab plus 13 chemotherapy from the perspective of Chinese healthcare system, to provide a basis for decision-14 making.
Keywords:
plus chemotherapy;
first line;
treatment extensive;
stage small;
extensive stage;
cost effectiveness
Journal Title: International journal of technology assessment in health care
Year Published: 2024
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: International journal of technology assessment in health care
Year Published: 2024
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!